Galderma stock after-hours at EUR 172.03: minus 0.95 percent versus prior close
Published on 10/06/2026 at 18:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Galderma stock was at EUR 172.03 after-hours at 6:44 p.m. CEST on October 6, 2026, according to Lang & Schwarz. The price was down EUR 1.65, or 0.95 percent, versus the Lang & Schwarz prior close of EUR 173.68.
Galderma stock during Tuesday’s session
The Lang & Schwarz quote showed a bid of EUR 171.35 and an ask of EUR 172.70. Galderma is listed on SIX under the ticker GALD. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Galderma stock.
Restylane reaches 30-year milestone
In a press release dated October 6, 2026, Galderma said it was marking 30 years since Restylane launched in Europe as the first hyaluronic acid injectable. The company said the portfolio has been supported by more than 80 clinical trials, 180 publications, approximately 407,000 patients evaluated for safety and 77 million treatments administered worldwide.
Galderma also highlighted product milestones from 2026, including European Union approval of Restylane Shaype for chin enhancement, approval of a new Restylane syringe in the European Union, the United States and Canada, and U.S. approval of Restylane Volyme for temple hollowing. The release said the portfolio had recently achieved European Union Medical Device Regulation certification for products using its NASHA HD, NASHA and OBT technologies.
Earlier shareholder approvals
In an April 22, 2026 release, Galderma said shareholders had approved all proposals at the company’s annual general meeting, including a gross dividend of CHF 0.35 per dividend-bearing share. Shareholders also approved board elections and the company’s 2025 annual financial statements, non-financial report and compensation report.
